Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives $11.67 Consensus Price Target from Brokerages

Shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) have earned a consensus recommendation of “Hold” from the seven analysts that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $13.25.

Several research firms have weighed in on MIST. Cowen increased their target price on Milestone Pharmaceuticals from $6.00 to $12.00 and gave the company an “outperform” rating in a research note on Thursday, July 23rd. Piper Sandler increased their target price on Milestone Pharmaceuticals from $3.00 to $8.00 and gave the company a “neutral” rating in a research note on Thursday, July 23rd. Zacks Investment Research lowered Milestone Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, July 3rd. Jefferies Financial Group raised Milestone Pharmaceuticals from a “hold” rating to a “buy” rating and increased their target price for the company from $3.00 to $15.00 in a research note on Friday, July 24th. Finally, Oppenheimer raised Milestone Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $18.00 target price on the stock in a research note on Wednesday.

In other Milestone Pharmaceuticals news, major shareholder De Solidarite Des Travai Fonds sold 19,863 shares of the stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $8.10, for a total value of $160,890.30. Following the completion of the sale, the insider now directly owns 2,754,920 shares in the company, valued at $22,314,852. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.16% of the stock is owned by corporate insiders.

An institutional investor recently bought a new position in Milestone Pharmaceuticals stock. UBS Group AG acquired a new position in shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 13,499 shares of the company’s stock, valued at approximately $25,000. UBS Group AG owned 0.05% of Milestone Pharmaceuticals at the end of the most recent reporting period. Institutional investors and hedge funds own 37.51% of the company’s stock.

Shares of MIST traded up $0.04 during trading hours on Tuesday, hitting $8.70. 1,489,189 shares of the stock traded hands, compared to its average volume of 14,801,032. Milestone Pharmaceuticals has a 1-year low of $1.69 and a 1-year high of $24.01. The firm has a market capitalization of $214.24 million, a PE ratio of -2.92 and a beta of 4.41. The business has a fifty day moving average of $4.58 and a 200-day moving average of $9.26.

Milestone Pharmaceuticals (NASDAQ:MIST) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.74) by $0.07. As a group, equities research analysts expect that Milestone Pharmaceuticals will post -2.01 earnings per share for the current year.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, develops and commercializes drugs for the treatment of cardiovascular indications. It offers Etripamil that completed Phase 2 clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as for treating Atrial Fibrillation and Angina.

See Also: What is an overbought condition?

Receive News & Ratings for Milestone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News